A new federal report found that unpaid Medicaid rebates from just 10 potentially misclassified drugs cost the government $1.3 billion over four years.

Pfizer has long expected I-O rivals to push aside kidney cancer med Sutent. But now, it’s getting in on the action.

La Jolla is prepping for its first-ever drug launch now that the FDA has blessed Giapreza, its treatment for dangerously low blood pressure.

In other news of note, Bristol-Myers, Roche and Pfizer won new indications for key cancer drugs and Boehringer inked a marketing settlement.

One of the fastest-growing classes of diabetes drugs now has a new contender, and it'll have to scramble to win share from its entrenched rivals.

In the absence of national drug pricing reform in the U.S., many states are taking the issue into their own hands.

Thanks to an FDA nod, Portola can finally go full throttle on its Bevyxxa launch with an inventory that had been on hold.

Exelixis shares soared Tuesday after its kidney cancer drug won a broader FDA approval expected to push it past $1 billion in peak sales.